AUPH
Price
$11.43
Change
-$0.18 (-1.55%)
Updated
Aug 7 closing price
Capitalization
1.5B
83 days until earnings call
GOSS
Price
$1.72
Change
-$0.02 (-1.15%)
Updated
Aug 8, 10:37 AM (EDT)
Capitalization
392.1M
90 days until earnings call
Interact to see
Advertisement

AUPH vs GOSS

Header iconAUPH vs GOSS Comparison
Open Charts AUPH vs GOSSBanner chart's image
Aurinia Pharmaceuticals
Price$11.43
Change-$0.18 (-1.55%)
Volume$3.33M
Capitalization1.5B
Gossamer Bio
Price$1.72
Change-$0.02 (-1.15%)
Volume$12.4K
Capitalization392.1M
AUPH vs GOSS Comparison Chart in %
Loading...
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUPH vs. GOSS commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Buy and GOSS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (AUPH: $11.43 vs. GOSS: $1.73)
Brand notoriety: AUPH and GOSS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 140% vs. GOSS: 133%
Market capitalization -- AUPH: $1.5B vs. GOSS: $392.1M
AUPH [@Biotechnology] is valued at $1.5B. GOSS’s [@Biotechnology] market capitalization is $392.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileGOSS’s FA Score has 0 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • GOSS’s FA Score: 0 green, 5 red.
According to our system of comparison, AUPH is a better buy in the long-term than GOSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 6 TA indicator(s) are bullish while GOSS’s TA Score has 2 bullish TA indicator(s).

  • AUPH’s TA Score: 6 bullish, 4 bearish.
  • GOSS’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, AUPH is a better buy in the short-term than GOSS.

Price Growth

AUPH (@Biotechnology) experienced а +23.63% price change this week, while GOSS (@Biotechnology) price change was -15.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

AUPH is expected to report earnings on Oct 30, 2025.

GOSS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUPH($1.51B) has a higher market cap than GOSS($392M). GOSS YTD gains are higher at: 90.692 vs. AUPH (27.283). AUPH has higher annual earnings (EBITDA): 86.5M vs. GOSS (-35.7M). AUPH has more cash in the bank: 315M vs. GOSS (258M). AUPH has less debt than GOSS: AUPH (81.8M) vs GOSS (203M). AUPH has higher revenues than GOSS: AUPH (260M) vs GOSS (125M).
AUPHGOSSAUPH / GOSS
Capitalization1.51B392M384%
EBITDA86.5M-35.7M-242%
Gain YTD27.28390.69230%
P/E Ratio26.58N/A-
Revenue260M125M208%
Total Cash315M258M122%
Total Debt81.8M203M40%
FUNDAMENTALS RATINGS
AUPH vs GOSS: Fundamental Ratings
AUPH
GOSS
OUTLOOK RATING
1..100
2171
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
50100
PRICE GROWTH RATING
1..100
3635
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GOSS's Valuation (57) in the Pharmaceuticals Major industry is in the same range as AUPH (67) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

GOSS's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AUPH (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

AUPH's SMR Rating (50) in the Biotechnology industry is somewhat better than the same rating for GOSS (100) in the Pharmaceuticals Major industry. This means that AUPH’s stock grew somewhat faster than GOSS’s over the last 12 months.

GOSS's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as AUPH (36) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

GOSS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as AUPH (100) in the Biotechnology industry. This means that GOSS’s stock grew similarly to AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHGOSS
RSI
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
72%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 12 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GOSS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PKCPY1.650.08
+4.84%
Pt Akr Corporindo
KYCCF381.527.02
+1.87%
Keyence Corp.
HELNF137.99N/A
N/A
HELVETIA PATRIA HLDG.
SKHRF0.50N/A
N/A
Stakeholder Gold Corp.
PMTYF0.06-0.01
-14.29%
Playmates Toys Ltd.

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
-1.55%
JSPR - AUPH
44%
Loosely correlated
-5.86%
VCYT - AUPH
39%
Loosely correlated
+15.48%
ROIV - AUPH
37%
Loosely correlated
-0.86%
GOSS - AUPH
37%
Loosely correlated
-12.88%
FOLD - AUPH
35%
Loosely correlated
-2.02%
More

GOSS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GOSS has been loosely correlated with MEIP. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GOSS jumps, then MEIP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GOSS
1D Price
Change %
GOSS100%
-12.88%
MEIP - GOSS
46%
Loosely correlated
+2.41%
ABEO - GOSS
42%
Loosely correlated
-1.88%
APVO - GOSS
41%
Loosely correlated
-1.38%
AUPH - GOSS
37%
Loosely correlated
-1.55%
SLDB - GOSS
37%
Loosely correlated
-7.61%
More